Biontaxis Receives €1.1 Million from the Government for Research in Gene Therapies

The Spanish company, Biontaxis, a spin-off of the Institut d’Investigació Germans Trias i Pujol de Badalona (Barcelona) specializing in neurological diseases, has obtained public funding from the Government for a value of €1.1 million.

Biontaxis has obtained funding through the European Recovery and Resilience Mechanism through the Center for Industrial Technological Development (Cdti) for its gene therapy project for Friedrich’s ataxia.

Friedreich’s ataxia is a neurodegenerative disease that is considered a rare disease. Mainly, it affects the ability to develop movements, such as walking and talking. The disease progressively aggravates incapacity and lack of autonomy. There is no cure, in case the cause is known, a defect in a gene that produces a mitochondrial protein called frataxin. The genetic problem produces a deficiency of this protein, which damages the neurons of the spinal cord and the cerebellum.

Read more about Biontaxis and find the most important business news of the day with the Born2Invest mobile app.

Biontaxis wants to develop and validate a gene therapy vector based on a new generation of adeno-associated virus

The company will use the resources to continue financing the development of a drug against Friedrich’s ataxia. The research is led by Antoni Matilla and Ivelisse Sánchez from the neurogenetics research group of the Germans Trias i Pujol Research Institute with the collaboration of neurologists from the neurology department of the Germans Trias Hospital and the Valdecilla de Santander Hospital.

The purpose of the project is to develop and validate a gene therapy vector based on a new generation of adeno-associated virus to be effective as a curative treatment in patients with Friedreich’s ataxia. The program is intended to finance experimental development projects in advanced therapies and personalized medicine in cooperation between companies and research organizations.

The next step for the company is to preclinically validate the drug in large animals to complete the preclinical validation as a phase prior to applying to the regulatory agencies for the corresponding authorization to bring the therapy to the clinical stage.

Friedrich’s ataxia is a rare disease that affects one in 40,000 people

Biointaxis was created in 2018 at the Germans Trias i Pujol Research Institute. Throughout its history, the company has received more than two million euros from the Center for Industrial Technological Development (Cdti), a public business entity whose objective is to promote innovation and technological development in Spanish companies, and from Caixa Capital Risc, CriteriaCaixa’s venture capital manager that invests in innovative companies in their initial and growth stages.

Friedrich’s ataxia is a rare disease that affects one in 40,000 people in the world and that appears between the ages of five and twenty, causing degeneration that ends up sending patients to a wheelchair, among many other problems. of health.

__

(Featured image by Furiosa-L via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.